SENTRY Trial Shows Survival, Spleen Benefits in Myelofibrosis: Claire Harrison, MD

Why It Matters

Demonstrating a survival benefit positions the selinexor‑ruxolitinib combination as a possible new frontline standard for myelofibrosis, addressing a long‑standing unmet need for disease‑modifying treatment.

Key Takeaways

• Selinexor + ruxolitinib cut spleen size more than ruxolitinib alone.
• 11‑month follow‑up showed statistically significant overall survival improvement.
• Combination lowered mutant driver allele fraction, hinting at disease modification.
• Adverse events were milder due to lower selinexor dose and ruxolitinib.
• Safety profile mirrors myeloma experience, but with fewer side effects.

Pulse Analysis

Myelofibrosis remains a challenging myeloproliferative disorder, with patients often experiencing splenomegaly, debilitating symptoms, and a median survival of only a few years. Since ruxolitinib’s approval 15 years ago, it has been the cornerstone therapy, yet it does not alter the underlying disease trajectory. Clinicians and investors alike have been watching for agents that can both control symptoms and extend life, creating a sizable market gap for disease‑modifying options.

The SENTRY trial (NCT04562389) addressed this gap by pairing selinexor, an XPO1 inhibitor with known activity against JAK/STAT and NF‑κB pathways, with standard‑dose ruxolitinib. Across multiple myelofibrosis subtypes, the combination achieved faster and deeper reductions in spleen volume than ruxolitinib alone, while overall symptom scores were comparable. Most strikingly, an overall survival advantage emerged at a median 11‑month follow‑up, correlating with both spleen shrinkage and a decrease in mutant driver allele fraction—signals that the regimen may be modifying disease biology rather than merely palliation.

If these results hold in longer‑term studies, the selinexor‑ruxolitinib duo could reshape treatment algorithms, moving from a symptom‑control paradigm to one that offers genuine survival benefit. Payers will likely reassess reimbursement models, and pharmaceutical firms may accelerate development of complementary agents targeting XPO1 or related pathways. For patients, a lower‑dose selinexor regimen promises a tolerable safety profile, potentially expanding eligibility to those previously excluded due to comorbidities. The trial thus marks a pivotal step toward a new standard of care in myelofibrosis.